RxDoctor Payments Data

Cheryl Goyne, MD

Neurology · Kenner, LANPI 1881702041

Payments from drug & device makers

$10,493in general payments, 2019–2025

Across 625 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Pfizer$549
  • Boston Scientific$547
  • SK Life Science, Inc.$489
  • Lilly USA, LLC$442
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$10,493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,493 in reported general payments places this provider in the 70th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$21,641
Medicare patients
111
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate114$153,649
UbrelvyUbrogepant88$122,542
IngrezzaValbenazine Tosylate14$118,736
BotoxOnabotulinumtoxina25$31,728
XcopriCenobamate23$29,379
Oxtellar XrOxcarbazepine16$26,905
Emgality PenGalcanezumab-Gnlm36$26,496
QuliptaAtogepant19$24,395
BelsomraSuvorexant47$22,728
BriviactBrivaracetam15$22,693
RexultiBrexpiprazole15$20,698
Ajovy AutoinjectorFremanezumab-Vfrm26$19,702
Lamictal OdtLamotrigine11$17,170
Memantine Hcl273$5,944
Pregabalin142$3,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$2,475$178,665132 claims
PfizerNurtec Odt$549$153,649114 claims
Neurocrine Biosciences, Inc.Ingrezza$211$118,73614 claims
SK Life Science, Inc.Xcopri$489$29,37923 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$13$26,90516 claims
UCB, Inc.Briviact$1,793$22,69315 claims
Otsuka America Pharmaceutical, Inc.Rexulti$126$20,69815 claims
Upsher-smith Laboratories LLCTopiramate$39$84059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 225 neurology providers in Louisiana.

Other neurology in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →